# A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

> **NCT05109728** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 65 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** [177Lu]Lu-DOTA-TATE
- **DRUG:** [68Ga]Ga-DOTA-TATE
- **OTHER:** Temozolomide
- **OTHER:** Radiotherapy

## Key facts

- **NCT ID:** NCT05109728
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-10
- **Primary completion:** 2025-12-03
- **Final completion:** 2027-07-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109728, "A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05109728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*